<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Senada Arabelovic</style></author><author><style face="normal" font="default" size="100%">Gina Sam</style></author><author><style face="normal" font="default" size="100%">Gerard E Dallal</style></author><author><style face="normal" font="default" size="100%">Paul F. Jacques</style></author><author><style face="normal" font="default" size="100%">Jacob Selhub</style></author><author><style face="normal" font="default" size="100%">Irwin H Rosenberg</style></author><author><style face="normal" font="default" size="100%">Ronenn Roubenoff</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Preliminary evidence shows that folic acid fortification of the food supply is associated with higher methotrexate dosing in patients with rheumatoid arthritis</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American College of Nutrition</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Antirheumatic Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Arthritis</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Interactions</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Folic Acid</style></keyword><keyword><style  face="normal" font="default" size="100%">Food</style></keyword><keyword><style  face="normal" font="default" size="100%">Food Supply</style></keyword><keyword><style  face="normal" font="default" size="100%">Fortified</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Methotrexate</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Rheumatoid</style></keyword><keyword><style  face="normal" font="default" size="100%">{Dose-Response} Relationship</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/17914133</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">26</style></volume><pages><style face="normal" font="default" size="100%">453–455</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND Fortification of the diet with folate has been used in the United States since 1997 to prevent neural tube defects in newborn babies. However, an increase in dietary folate intake could theoretically reduce the effectiveness of the anti-folate medication, methotrexate (MTX) in treating rheumatoid arthritis (RA) and other inflammatory diseases.
OBJECTIVE To investigate whether dietary fortification with folic acid interferes with MTX function in patients with RA.
METHODS We computed MTX dose per patient per year for the years 1988 to 1999 and plotted these against time, comparing the overall mean MTX dose before and after 1997, when dietary fortification with folic acid was instituted in the USA. Thirty-six subjects met eligibility criteria.
RESULTS Mean annual MTX dose was stable between 1988 and 1996 (12.4 +/- 4.0mg), but then rose linearly from 1997 to 1999 (16.6 +/- 5.1 mg, p &lt; 0.001).
CONCLUSIONS This preliminary study suggests that folic acid supplementation may contribute to higher MTX dosing in patients with RA.</style></abstract><notes><style face="normal" font="default" size="100%">{PMID:} 17914133</style></notes></record></records></xml>